Abstract:Modulation of the antitumor immune response through the engagement of NKG2D receptors with their ligands (L) on targets represents a promising therapeutic approach against cancer. In this study, we tested the effect of valproic acid (VPA), a histone deacetylase (HDAC) inhibitor, on the expression of NKG2D ligands in myeloma cells. We demonstrated that VPA was able to upregulate both protein and mRNA expression of major histocompatibility complex class I-related chain (MIC) A/B and UL16-binding protein (ULBP) 2 without any significant effect on the expression of ULBP1, ULBP3, and ULBP4 or induction of other natural killer (NK) cell ligands, such as NKp30-L, NKp44-L, and NKp46-L in myeloma cells. A 51Cr release assay and degranulation assay indicated that the induction of MICA/B and ULBP2 augmented NK cell-mediated lysis of myeloma cells, which was abolished by the addition of a blocking NKG2D antibody. Activation of constitutively phosphorylated extracellular signal-regulated kinase (ERK) by VPA is essential for the up-regulation of MICA/B and ULBP2 expressions. Inhibition of ERK using ERK inhibitor PD98059 decreased both MICA/B and ULBP2 expressions and NK cell cytotoxicity. Furthermore, overexpression of constitutively active ERK in ARK resulted in increased MICA/B and ULBP2 expressions and enhanced NK cell lysis. These data indicate that increased sensitivity of VPA-treated myeloma cells to NK cell lysis is caused by higher NKG2D ligand expression, resulting from more active ERK signaling pathway. Our results provide evidence that targeting ERK signaling pathway may be an additional mechanism supporting the antimyeloma activity of HDAC inhibitors and suggest its possible immunotherapeutic value for myeloma treatment.

The Mood Stabilizer Valproic Acid Activates Mitogen-activated Protein Kinases and Promotes Neurite Growth*

Valproate robustly enhances AP-1 mediated gene expression.

The Mood Stabilizer Valproic Acid Induces Proliferation and Myelination of Rat Schwann Cells

The mood stabilizer valproate activates human FGF1 gene promoter through inhibiting HDAC and GSK-3 activities

The Mood‐Stabilizing Agent Valproate Inhibits the Activity of Glycogen Synthase Kinase‐3

Valproic acid activates ERK-1/2 signaling pathway in the rat hippocampus and frontal cortex

Valproic Acid Influences MTNR1A Intracellular Trafficking and Signaling in a β-Arrestin 2-Dependent Manner

Effects Of Valproic Acid On Axonal Regeneration And Recovery Of Motor Function After Peripheral Nerve Injury In The Rat

PI3K/AKT/mTOR Signaling Mediates Valproic Acid-Induced Neuronal Differentiation of Neural Stem Cells through Epigenetic Modifications.

C-Jun Amino-Terminal Kinase is Involved in Valproic Acid-Mediated Neuronal Differentiation of Mouse Embryonic NSCs and Neurite Outgrowth of NSC-Derived Neurons

Valproic Acid Protects Primary Dopamine Neurons from MPP+-Induced Neurotoxicity: Involvement of GSK3β Phosphorylation by Akt and ERK Through the Mitochondrial Intrinsic Apoptotic Pathway

Divergent effects of lithium and sodium valproate on brain-derived neurotrophic factor (BDNF) production in human astrocytoma cells at therapeutic concentrations

The Mood Stabilizer Valproic Acid Stimulates GABA Neurogenesis from Rat Forebrain Stem Cells

Search for common targets of lithium and valproic acid identifies novel epigenetic effects of lithium on the rat leptin receptor gene

Valproic Acid Modifies Synaptic Structure and Accelerates Neurite Outgrowth Via the Glycogen Synthase Kinase‐3β Signaling Pathway in an Alzheimer's Disease Model

Pi3k/Akt/Mtor Signaling Mediates Valproic Acid-Induced Neuronal Differentiation of Neural Stem Cells Through Epigenetic Modifications

Valproic Acid Upregulates NKG2D Ligand Expression Through an ERK-dependent Mechanism and Potentially Enhances NK Cell-mediated Lysis of Myeloma

Valproic acid exerts differential effects on cytokine synthesis in human peripheral lymphocytes

Microinjection of Valproic Acid into the Ventrolateral Orbital Cortex Enhances Stress-Related Memory Formation.

Induction of osteogenic differentiation of human mesenchymal stem cells by histone deacetylase inhibitors

Valproate Administration to Mice Increases Histone Acetylation and 5-Lipoxygenase Content in the Hippocampus.